Cargando…
Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
BACKGROUND: Psychosis is rare in untreated patients with Parkinson's disease (PD) but the prevalence rises to 40% during dopaminergic treatment. So far, no systematic comparison of the psychogenic potential of different dopaminergic drugs had been performed. METHODS: Eighty PD patients with psy...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704166/ https://www.ncbi.nlm.nih.gov/pubmed/19515253 http://dx.doi.org/10.1186/1471-2377-9-23 |
_version_ | 1782168906607099904 |
---|---|
author | Ecker, Daniel Unrath, Alexander Kassubek, Jan Sabolek, Michael |
author_facet | Ecker, Daniel Unrath, Alexander Kassubek, Jan Sabolek, Michael |
author_sort | Ecker, Daniel |
collection | PubMed |
description | BACKGROUND: Psychosis is rare in untreated patients with Parkinson's disease (PD) but the prevalence rises to 40% during dopaminergic treatment. So far, no systematic comparison of the psychogenic potential of different dopaminergic drugs had been performed. METHODS: Eighty PD patients with psychotic episodes were compared to an age-matched control group of PD patients without psychotic episodes (n = 120) in a cross-sectional retrospective study. RESULTS: We found a positive correlation between psychotic episodes and dementia, number of concomitant medication, and pergolide intake. Odds ratio calculation confirmed the association with dementia. With respect to dopaminergic treatment, pergolide showed the highest odds ratio, levodopa the lowest. An adjusted logistic regression model confirmed the strong association with psychotic episodes and pergolide and no association with levodopa (adjusted odds ratio 2.01 and 0.11, respectively). CONCLUSION: The analysis indicates that dementia and concomitant medication are factors in PD associated with psychotic symptoms. Furthermore, different dopaminergic drugs showed markedly different associations with psychotic symptoms |
format | Text |
id | pubmed-2704166 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27041662009-07-01 Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study Ecker, Daniel Unrath, Alexander Kassubek, Jan Sabolek, Michael BMC Neurol Research Article BACKGROUND: Psychosis is rare in untreated patients with Parkinson's disease (PD) but the prevalence rises to 40% during dopaminergic treatment. So far, no systematic comparison of the psychogenic potential of different dopaminergic drugs had been performed. METHODS: Eighty PD patients with psychotic episodes were compared to an age-matched control group of PD patients without psychotic episodes (n = 120) in a cross-sectional retrospective study. RESULTS: We found a positive correlation between psychotic episodes and dementia, number of concomitant medication, and pergolide intake. Odds ratio calculation confirmed the association with dementia. With respect to dopaminergic treatment, pergolide showed the highest odds ratio, levodopa the lowest. An adjusted logistic regression model confirmed the strong association with psychotic episodes and pergolide and no association with levodopa (adjusted odds ratio 2.01 and 0.11, respectively). CONCLUSION: The analysis indicates that dementia and concomitant medication are factors in PD associated with psychotic symptoms. Furthermore, different dopaminergic drugs showed markedly different associations with psychotic symptoms BioMed Central 2009-06-10 /pmc/articles/PMC2704166/ /pubmed/19515253 http://dx.doi.org/10.1186/1471-2377-9-23 Text en Copyright © 2009 Ecker et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ecker, Daniel Unrath, Alexander Kassubek, Jan Sabolek, Michael Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study |
title | Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study |
title_full | Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study |
title_fullStr | Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study |
title_full_unstemmed | Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study |
title_short | Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study |
title_sort | dopamine agonists and their risk to induce psychotic episodes in parkinson's disease: a case-control study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704166/ https://www.ncbi.nlm.nih.gov/pubmed/19515253 http://dx.doi.org/10.1186/1471-2377-9-23 |
work_keys_str_mv | AT eckerdaniel dopamineagonistsandtheirrisktoinducepsychoticepisodesinparkinsonsdiseaseacasecontrolstudy AT unrathalexander dopamineagonistsandtheirrisktoinducepsychoticepisodesinparkinsonsdiseaseacasecontrolstudy AT kassubekjan dopamineagonistsandtheirrisktoinducepsychoticepisodesinparkinsonsdiseaseacasecontrolstudy AT sabolekmichael dopamineagonistsandtheirrisktoinducepsychoticepisodesinparkinsonsdiseaseacasecontrolstudy |